Repros Therapeutics set for gap up at the open

Shares of thinly-traded Repros Therapeutics (NASDAQ:RPRX) are up 14% premarket on healthy volume in response to its report of successful results in a Phase 3 clinical trial comparing its secondary hypogonadism treatment Androxal (single isomer of clomiphene citrate) to Abbvie's (NYSE:ABBV) Androgel (testosterone gel) and placebo.

In the study, called ZA-305, Androxal demonstrated superiority in the two co-primary endpoints of percent change from baseline in average sperm concentration and percent of subjects considered to be responders.

23.8% of topical testosterone (Topical T) subjects were below 10M sperm/mL at the end of the study compared to 2.3% for Androxal and 2.4% for placebo. Baseline sperm concentration increased 5.9% for Androxal versus a reduction of 33.3% from baseline for the Topical T group. Androxal responder rate was 65.9% compared to 33.3% for Topical T.

Mean change in sperm concentration from baseline was +14% for Androxal, -30% for Androgel and +7% for placebo.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs